Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
PHASE3
This study (contRAst 3 \[202018: NCT04134728\]) is a Phase 3, randomized, m...
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
PHASE3
This study \[contRAst 2 (201791: NCT03970837)\] is a phase 3, randomized, m...
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
N/A
This study will be conducted to observe the disease activity change of Conv...
Status
Completed
Location
Eisai Trial Site # 1
Start Date
2017-09-11
Trial ID
NCT03264703
Effect of TNF-Inhibition Combined With Conventional DMARDs on Cervical Pannus in Patients With RA and Cervical Spine Involvement
N/A
Atlantoaxial subluxation (AAS) is a complication of rheumatoid arthritis (R...
Status
Unknown
Location
University Hospital Zurich, Division of Rheumatology
EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis
N/A
The purpose of this study is to evaluate the percentage of participants tre...